Introduction {#section1-2150131917705206}
============

Fecal occult blood tests (FOBTs) are used to detect small amounts of blood in the stool, which can indicate the presence of advanced adenomatous polyps (AAP) or colorectal cancer (CRC).^[@bibr1-2150131917705206],[@bibr2-2150131917705206]^ Two types of FOBTs are available---guaiac (gFOBT) and fecal immunochemical tests (FITs). There is general agreement that FITs have better test characteristics and are easier for patients to use compared with gFOBTs.^[@bibr1-2150131917705206],[@bibr3-2150131917705206][@bibr4-2150131917705206][@bibr5-2150131917705206][@bibr6-2150131917705206]-[@bibr7-2150131917705206]^ However, the many brands of FIT on the market and limited information on test characteristics for the outcomes of AAP or CRC make it difficult to decide which FIT to choose.

The gFOBT was developed in the 1860s for CRC screening.^[@bibr8-2150131917705206],[@bibr9-2150131917705206]^ FITs were developed in the 1970s and use antibodies directed against the globin component of hemoglobin to detect blood in the stool.^[@bibr9-2150131917705206][@bibr10-2150131917705206]-[@bibr11-2150131917705206]^ The US Preventive Services Task Force, the American College of Gastroenterology, and the American Cancer Society promote the use of FIT over gFOBT in CRC screening.^[@bibr12-2150131917705206][@bibr13-2150131917705206][@bibr14-2150131917705206]-[@bibr15-2150131917705206]^ FITs are preferred by patients over colonoscopy^[@bibr3-2150131917705206],[@bibr4-2150131917705206]^ and there are no dietary or medicine restrictions, unlike with the gFOBT.^[@bibr1-2150131917705206],[@bibr5-2150131917705206],[@bibr6-2150131917705206]^ Modeling studies indicate there is no difference in life-years gained when comparing a CRC screening strategy of annual FIT testing with a colonoscopy every 10 years.^[@bibr16-2150131917705206]^ FITs use 2 immunoassay techniques: an automated laboratory instrument-based immunoturbidometric test and a lateral flow immunochromatographic analysis for point-of-care testing.^[@bibr1-2150131917705206]^

There are numerous FIT products available. The purposes of this research were to summarize: (1) the FITs currently available in the United States based on the Food and Drug Administration (FDA) and product websites, (2) the 2014 pathology proficiency testing (PT) program results regarding FITs, and (3) the literature related to the test characteristics of FITs available in the United States to detect AAP and/or CRC.

Background {#section2-2150131917705206}
==========

FDA Website and FOBT Approval via the 510(k) Process {#section3-2150131917705206}
----------------------------------------------------

The US Department of Health and Human Services FDA website has a section for medical devices, the Clinical Laboratory Improvement Amendments (CLIA) database, that lists the commercially marketed test systems catalogued by the FDA since 2000, as well as those catalogued by the Centers for Disease Control and Prevention prior to that time ([www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfclia/search.cfm](http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfclia/search.cfm)). This database lists FOBTs that have been cleared by the FDA and associated documentation.

FDA FOBT Test Complexity {#section4-2150131917705206}
------------------------

CLIA legislation passed by Congress in 1988 was established to ensure accuracy, reliability, and timeliness of patient test results regardless of where the test was performed.^[@bibr17-2150131917705206]^ FOBTs, both waived and moderate complexity, are classified as class II devices. Waived tests are "simple laboratory examinations and procedures that have an insignificant risk of an erroneous result."^[@bibr17-2150131917705206]^ To perform waived tests, the healthcare provider needs to have a CLIA Certificate of Waiver. Moderate complexity tests have to be analyzed in a certified pathology laboratory. Class indicates the intended use of the device and the risk the device poses to a patient with class I being the least risk and class III the greatest risk. For class II tests, a 510(k) application to the FDA is required for clearance and then marketing.

All certified pathology laboratories are required to participate in a PT program for all analytes they test for. The Centers for Medicare & Medicaid Services (CMS), through CLIA, regulates approximately 252 000 laboratory entities where FOBTs are analyzed.^[@bibr18-2150131917705206]^

FDA Document Number {#section5-2150131917705206}
-------------------

The FDA requires a 510(k) application to be submitted prior to marketing and selling of FOBTs. The 510(k) must demonstrate the FOBT is substantially equivalent to a device already legally marketed. An application submitter must compare their FOBT to one or more similarly marketed devices to support their substantial equivalency claims. The FDA then determines if the data provided supports the claim of substantial equivalence and categorizes the FOBT as a new device, substantially equivalent for marketing in the United States, or as a device modification. Listed on the 510(k) are the predicate device names and numbers, which indicate the device is safe and effective/substantially equivalent to its predicate. Contrary to what one might see on company websites, the FDA does not "approve" any FOBTs, but provides clearance after review of a 510(k) application.

Methods {#section6-2150131917705206}
=======

The University of Iowa Institutional Review Board reviewed this project and determined it was not human subjects research. Data were collected and summarized from the FDA CLIA database, all CMS-approved PT programs in the United States for the calendar year 2014, and a detailed, literature review on FIT characteristics published in the English language where colonoscopy was used as the gold standard.

FDA CLIA Database {#section7-2150131917705206}
-----------------

The CLIA database was searched and 122 FOBTs were listed as of July 22, 2016. For each FOBT, a search of the Internet using the name of the product and manufacturer, guaiac, fecal immunochemical, and fecal occult blood test was conducted to determine whether the product was a gFOBT or a FIT. If the product could not be found on the Internet, a search of PubMed was conducted.

Proficiency Testing Programs {#section8-2150131917705206}
----------------------------

Pathology laboratories participate in PT programs to ensure that procedures for analyte testing give accurate results. Currently, there are 7 PT programs in the United States that distribute samples for FOBTs.^[@bibr19-2150131917705206]^ PT program 2014 data were obtained from the programs' Internet posting or customer service. The programs included (1) American Academy of Family Physicians Proficiency Testing (AAFP-PT), (2) American Association of Bioanalysts (AAB) Proficiency Testing Service, (3) American College of Physicians (ACP) Medical Laboratory Evaluation (MLE) Program, (4) American Proficiency Institute (API), (5) the College of American Pathologists (CAP)--Surveys (large laboratories), (6) the CAP External Comparative Evaluation for Laboratories EXCEL (small laboratories), and (7) Wisconsin State Laboratory of Hygiene (WSLH). Results that included specific FOBT test system/manufacturer names were obtained from 6 of the 7 PT programs. The AAFP-PT testing service was only able to provide the data in aggregate for manufacturers. Thus, their results were not included in this analysis.

Data from PT programs did not indicate the superiority or inferiority of instruments, reagents, or other materials.^[@bibr20-2150131917705206]^ PT is required on all analytes conducted in pathology laboratories that are not waived under CLIA. However, if waived tests are run in a CLIA-certified lab, then it is to the advantage of the laboratories to also test those analytes that are waived.^[@bibr21-2150131917705206]^ If waived FITs are performed in a physician's office, a CLIA Certificate of Waiver must be obtained and PT is not required.^[@bibr17-2150131917705206]^

gFOBTs were eliminated from the PT sensitivity/specificity analysis because FITs are now preferred for CRC screening.^[@bibr12-2150131917705206],[@bibr13-2150131917705206],[@bibr15-2150131917705206]^ The PT review included 15 distinct FITs and a total of 12 730 samples.

Literature Review {#section9-2150131917705206}
-----------------

As of March 11, 2016, there were 447 publications listed in PubMed using the search term "fecal immunochemical test." There were 72 articles for review after excluding those not written in English, non-research articles and research that did not assess FIT accuracy for AAP and/or CRC in human subjects. After reviewing these abstracts, 26 were found to have information on the accuracy of FITs, with all subjects undergoing a colonoscopy or flexible sigmoidoscopy after FOBT collection.^[@bibr22-2150131917705206][@bibr23-2150131917705206][@bibr24-2150131917705206][@bibr25-2150131917705206][@bibr26-2150131917705206][@bibr27-2150131917705206][@bibr28-2150131917705206][@bibr29-2150131917705206][@bibr30-2150131917705206][@bibr31-2150131917705206][@bibr32-2150131917705206][@bibr33-2150131917705206][@bibr34-2150131917705206][@bibr35-2150131917705206][@bibr36-2150131917705206][@bibr37-2150131917705206][@bibr38-2150131917705206][@bibr39-2150131917705206][@bibr40-2150131917705206][@bibr41-2150131917705206][@bibr42-2150131917705206][@bibr43-2150131917705206][@bibr44-2150131917705206][@bibr45-2150131917705206][@bibr46-2150131917705206]-[@bibr47-2150131917705206]^ Two authors (JMD, BTL) reviewed these papers independently to find the results of FIT test accuracy for AAP and/or CRC. After reviewing the articles, those that presented results of FITs no longer on the market, such as FlexSure OBT and HemeSelect, were excluded,^[@bibr23-2150131917705206],[@bibr24-2150131917705206],[@bibr40-2150131917705206],[@bibr41-2150131917705206]^ not used in the United States,^[@bibr30-2150131917705206],[@bibr34-2150131917705206],[@bibr35-2150131917705206]^ not named in the paper,^[@bibr36-2150131917705206]^ and those where colonoscopy was not used on all subjects.^[@bibr24-2150131917705206],[@bibr36-2150131917705206],[@bibr40-2150131917705206],[@bibr41-2150131917705206]^ For papers presenting sequential results of incremental study populations,^[@bibr26-2150131917705206],[@bibr31-2150131917705206],[@bibr32-2150131917705206],[@bibr37-2150131917705206],[@bibr39-2150131917705206],[@bibr42-2150131917705206],[@bibr45-2150131917705206],[@bibr46-2150131917705206]^ we chose the paper with the largest subject number^[@bibr26-2150131917705206],[@bibr39-2150131917705206],[@bibr46-2150131917705206]^ since that provided the most reliable estimates of test accuracy for AAP and/or CRC. Thus, 13 papers were found in the English language on test characteristics of FITs, using colonoscopy as the gold standard.^[@bibr22-2150131917705206],[@bibr25-2150131917705206][@bibr26-2150131917705206][@bibr27-2150131917705206][@bibr28-2150131917705206]-[@bibr29-2150131917705206],[@bibr33-2150131917705206],[@bibr38-2150131917705206],[@bibr39-2150131917705206],[@bibr43-2150131917705206],[@bibr44-2150131917705206],[@bibr46-2150131917705206],[@bibr47-2150131917705206]^

Data Analysis {#section10-2150131917705206}
-------------

The PT programs' results for each FIT brand evaluated in 2014 were reviewed in detail and summarized. At each testing interval, 2 or 3 blinded synthetic fecal samples were sent to participating pathology laboratories and analyzed for the presence of spiked hemoglobin with FITs used in their laboratory. Results were reported back as either positive or negative for hemoglobin. PT programs reported whether the results were correct or incorrect for each FIT and the overall percentages correct/incorrect were tallied across FIT devices. The test system/manufacturer sensitivity and specificity for synthetic fecal samples and the overall sensitivity and specificity for each FIT device across testing programs, along with 95% Agresti-Coull binomial proportion confidence intervals were calculated,^[@bibr48-2150131917705206]^ using SAS version 9.4 (SAS, Inc, Cary, NC).

Results {#section11-2150131917705206}
=======

FDA CLIA Database {#section12-2150131917705206}
-----------------

The initial FIT listed in the CLIA database was the SmithKline FlexSure OBT, which is no longer on the market. Historically, CMS reports that early FITs were considered substantially equivalent to the first gFOBT.^[@bibr49-2150131917705206]^

Based on the search for FOBTs in the CLIA database, 122 FOBT analytes with 60 distinct 510(k) numbers were retrieved; 65 were FITs, 56 were gFOBT, and one was an orthotolidine reagent method (see [Figure 1](#fig1-2150131917705206){ref-type="fig"}). Of the 65 FITs listed, 60 are CLIA-waived, and 5 are moderate complexity, non-CLIA-waived (See [Table 1](#table1-2150131917705206){ref-type="table"}). There are 25 distinct 510(k) numbers for the 60 CLIA-waived FITs and 3 distinct 510(K) numbers for the automated FITs. Only 2 automated FITs are sold in the US Test systems with the same 510(k) numbers have the same manufacturer (see [Table 1](#table1-2150131917705206){ref-type="table"}). For example, Immunostics, Inc, is listed as the test system/manufacturer for these 4 FITs, hema-screen SPECIFIC Immunochemical Fecal Occult Blood Test, Consult Diagnostics iFOBT, Henry Schein OneStep+ iFOBT, and Select Diagnostics Immunochemical Fecal Occult Blood Test. These 4 FITs have identical 510(k) numbers but are sold under different labels. Three of these 4 FITs are included in the PT program results.

![FDA CLIA database fecal occult blood search focusing on distinct FITs available in the United States and number tested by proficiency testing programs. FDA, Food and Drug Administration; CLIA, Clinical Laboratory Improvement Amendments; FIT, fecal immunochemical test.](10.1177_2150131917705206-fig1){#fig1-2150131917705206}

###### 

FDA 510(k) Document Number and Test System/Manufacturer^[a](#table-fn2-2150131917705206){ref-type="table-fn"}^ for CLIA-Waived and Moderate Complexity FITs.^[b](#table-fn3-2150131917705206){ref-type="table-fn"}^

![](10.1177_2150131917705206-table1)

  No. FITs                   No. 510(k) numbers   510(k) Document Number                                                    Test System/Manufacturer                                                                             Effective Date (mm/dd/yy)
  -------------------------- -------------------- ------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ---------------------------
  CLIA-waived FITs                                                                                                                                                                                                               
  1                          1                    E990036                                                                   Alfa Scientific Designs Instant-View Fecal Occult Blood Test (Cassette)                              07/23/1999
  2                          2                    K002457                                                                   ENTERIX INSURE FECAL OCCULT BLOOD TEST                                                               01/31/2001
  3                                               K002457                                                                   ENTERIX INSURE FECAL IMMUNOCHEMICAL TEST                                                             10/16/2003
  4                          3                    K021423                                                                   ALFA SCIENTIFIC DESIGNS - ISCREEN FECAL OCCULT BLOOD TEST                                            02/25/2005
  5                                               K021423                                                                   QuickVue iFOB Test (Immunochemical Fecal Occult Blood) (Cassette)                                    11/9/2005
  6                          4                    K041202                                                                   Clarity Hemosure One-Step Immunological Fecal Occult Blood Test                                      03/30/2005
  7                                               K041202                                                                   HEMOSURE ONE-STEP FECAL OCCULT BLOOD TEST                                                            09/8/2004
  8                          5                    K041297                                                                   Clearview Ultra FOB Test                                                                             08/18/2004
  9                                               K041297                                                                   OC-Light iFOB Test                                                                                   03/24/2011
  10                                              K041297                                                                   POLYMEDCO POLY STAT OC-LIGHT FOB TEST                                                                08/18/2004
  11                         6                    K051806                                                                   Care Fecal Occult Blood Test                                                                         10/7/2005
  12                         7                    K052598                                                                   Care Diagnostic Clarity IFOB Test                                                                    01/26/2010
  13                                              K052598                                                                   immoCARE Fecal Occult Blood Test                                                                     03/22/2006
  14                         8                    K060463                                                                   Consult Diagnostics Immunochemical Fecal Occult Blood Test (iFOBT)                                   07/8/2010
  15                                              K060463                                                                   Henry Schein OneStep+ iFOBT                                                                          03/5/2009
  16                                              K060463                                                                   Immunostics Inc. hema-screen SPECIFIC Immunochemical Fecal Occult Blood Test                         06/15/2006
  17                                              K060463                                                                   Select Diagnostics Immunochemical Fecal Occult Blood Test                                            02/8/2007
  18                         9                    K060930                                                                   ENTERIX INSURE II FECAL IMMUNOCHEMICAL TEST                                                          08/3/2006
  19                                              K060930                                                                   InSure Quik Fecal Immunochemical Test (F.I.T.)                                                       01/26/2007
  20                         10                   K060953                                                                   OcculTech Fecal Occult Blood Rapid Test                                                              09/22/2006
  21                         11                   K061065                                                                   CLIAwaived Inc. Rapid Fecal Occult Blood Test                                                        11/9/2009
  22                                              K061065                                                                   Teco Rapid Fecal Occult Blood (FOB) Card Test                                                        08/9/2006
  23                                              K061065                                                                   BTNX Inc. Rapid Response Immunological Fecal Occult Blood Test (IFOBT)                               07/22/2008
  24                         12                   K063673                                                                   Innovacon FOB Flipcard Fecal Occult Blood Test                                                       03/7/2007
  25                         13                   K063693                                                                   Centralcheck iFOBT Complete Fecal Occult Blood Test                                                  11/16/2010
  26                                              K063693                                                                   Forsure One Step Fecal Occult Blood (FOB) Screen Card Test                                           05/16/2007
  27                                              K063693                                                                   GERMAINE LABORATORIES AimStep Immunological Fecal Occult Blood Test (iFOBT)                          09/9/2009
  28                                              K063693                                                                   Germaine Laboratories Compliance Gold iFOB (immunological fecal occult blood)Test                    07/1/2008
  29                                              K063693                                                                   Healthcare Provider Direct OneStep Fecal Occult Blood (FOB) Screen Card Test                         07/22/2008
  30                                              K063693                                                                   Inverness Medical Clearview iFOBT Complete Fecal Occult Blood Test                                   03/1/2010
  31                                              K063693                                                                   Jant Pharmacal Accutest Immunological Fecal Occult Blood Test (iFOBT)                                12/4/2008
  32                         14                   K070660                                                                   Alfa Scientific Designs Fecal Occult Blood (FOB) Self-Test                                           06/28/2007
  33                                              K070660                                                                   Alfa Scientific Designs Instant-View Fecal Occult Blood (FOB) Self-Test (Cassette)                   06/28/2007
  34                                              K070660                                                                   BTNX Inc. Clarity Fecal Occult Blood (FOB) Self Test                                                 10/5/2007
  35                                              K070660                                                                   BTNX Inc. Know Fecal Occult Blood (FOB) Self Test                                                    10/5/2007
  36                                              K070660                                                                   BTNX Inc. Rapid Response Fecal Occult Blood (FOB) Self Test                                          10/5/2007
  37                                              K070660                                                                   Medline Fecal Occult Blood Test (Cassette)                                                           08/22/2013
  38                         15                   K071242                                                                   AmeriTek dBest One Step Occult Blood Test                                                            03/12/2008
  39                         16                   K073431                                                                   Jant Pharmacal Accutest Dual Sample Immunological Fecal Occult Blood (iFOB) Test                     12/4/2008
  40                                              K073431                                                                   Tianjin New Bay Bioresearch Co. Ltd. ForeSure IFOB Dual-Sample Fecal Occult Blood Screen Card Test   02/22/2012
  41                         17                   K080812                                                                   BECKMAN COULTER HEMOCCULT ICT                                                                        07/1/2008
  45                         18                   K901064                                                                   CHEMICON MONOHAEM                                                                                    05/15/2003
  42                         19                   K961062                                                                   SmithKline FlexSure OBT                                                                              02/28/1997
  43                                              K961062                                                                   BECKMAN COULTER HEMOCCULT ICT                                                                        05/26/2004
  44                                              K961062                                                                   BECKMAN COULTER HEMOCCULT ICT                                                                        06/28/2004
  46                         20                   K100031                                                                   American IVD Biotechnology Services Inc. FOB/CRC Advanced+                                           10/4/2010
  47                                              K100031                                                                   BTNX Inc. Rapid Response Fecal Immunochemical Test (FIT)                                             10/4/2010
  48                                              K100031                                                                   IND Diagnostic Inc. One Step Fecal Occult Blood Test                                                 07/28/2010
  49                                              K100031                                                                   Medline iFOB One-Step Immunological Fecal Occult Blood Test                                          04/19/2012
  50                         21                   K100817/CR140487^[c](#table-fn4-2150131917705206){ref-type="table-fn"}^   Medline iFOB TEST                                                                                    06/26/2015
  51                                              K100817                                                                   Princeton BioMeditech BioSign Immunochemical Fecal Occult Blood Test (iFOBT)                         07/8/2010
  52                                              K100817                                                                   Status iFOBT                                                                                         10/19/2011
  53                                              K100817/CR150328                                                          Sekisui Diagnostics LLC OSOM iFOB Test                                                               07/28/2015
  54                         22                   K102664/CR160124                                                          Germaine Laboratories Inc. Compliance Gold Fecal Occult Blood Test                                   04/20/2016
  55                         23                   K110309                                                                   Orient Gene Biotech - One Step Rapid FOB                                                             09/20/2011
  56                                              K110309                                                                   Rapid Response(TM) FIT - Fecal Immunochemical Test                                                   04/22/2014
  57                                              K110309/CR150438                                                          Tanner Scientific IFOB One Step Rapid Test                                                           09/14/2015
  58                                              K110309/CR150489                                                          Clarity Diagnostics One-Step Fecal Occult Blood Test                                                 10/6/2015
  59                         24                   K121397                                                                   OSOM® iFOB Test OSOM® iFOBT Control Kit                                                              01/3/2013
  60                         25                   K143325/CR140487                                                          Eiken Chemical Co. LTD OC-Light S FIT                                                                08/24/2015
  Moderate Complexity FITs                                                                                                                                                                                                       
  61                         1                    K132167                                                                   Boditech Med Inc. i-CHROMA iFOB with i-CHROMA Reader                                                 05/6/2014
  62                         2                    K092330                                                                   OC Auto Sensor DIANA iFOB                                                                            12/5/2013
  63                                              K092330                                                                   OC Auto Micro 80 iFOB                                                                                12/5/2013
  64                         3                    K041408                                                                   Polymedco OC Auto Micro 80 analyzer                                                                  05/23/2005
  65                                              K092330^[d](#table-fn5-2150131917705206){ref-type="table-fn"}^            Polymedco OC-Sensor DIANA iFOB Test                                                                  01/20/2010

Abbreviations: FDA, Food and Drug Administration; CLIA, Clinical Laboratory Improvement Amendments; FIT, fecal immunochemical test.

Test System/Manufacturer listed as presented on FDA CLIA Database.

Shading indicates the same test marketed under different names.

On March 21, 2014, CLIA started filing using CR as a prefix, with the Parent Document number with a prefix of K.

The correct document number should be K041408 (Helen Landicho, Senior Vice President of Regulatory Affairs, Polymedco).

Of the 60 CLIA-waived FITs, 24 FITs with 16 unique 510(k) numbers are available for purchase in the United States (see [Table 2](#table2-2150131917705206){ref-type="table"}). The 5 moderate complexity FITs have 3 unique 510(k) numbers, but only 2 are available in the United States (OC-Auto Micro 80 and OC-Sensor Diana). These 2 use identical liquid-vial collection containers, reagent, calibrator, and controls, but the analyzers have different throughput rates.

###### 

CLIA-Waived and Moderate Complexity FITs Available for Purchase in United States as of July 22, 2016 With FDA Applicant, Respective 510(k) Document Number, Effective Date, and Accuracy in Human Studies.^[a](#table-fn7-2150131917705206){ref-type="table-fn"}^

![](10.1177_2150131917705206-table2)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No. FITs               No. 510(k) number   Test System/Manufacturer\                                                                                                                                                                    \% of FITs in PT Programs\                                     510(k) Document Number   Colonoscopic Histology Results/No. of Subjects in Study   Detection Limits                                                     Sensitivity/Specificty/PPV
                                             Applicant/(Effective Date)                                                                                                                                                                   (N = 12 730)                                                                                                                                                                                                           
  ---------------------- ------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------- ------------------------ --------------------------------------------------------- -------------------------------------------------------------------- ----------------------------
  CLIA-waived FITs                                                                                                                                                                                                                                                                                                                                                                                                                                               

  1                      1                   Enterix Insure Fecal Immunochemical Test^[b](#table-fn8-2150131917705206){ref-type="table-fn"},[c](#table-fn9-2150131917705206){ref-type="table-fn"}^\                                       0.50                                                           K002457                                                                                                                                                 None
                                             Enterix, Inc. (10/16/2003)                                                                                                                                                                                                                                                                                                                                                                                          

  2                      2                   QuickVue IFOB Test^[b](#table-fn8-2150131917705206){ref-type="table-fn"}^\                                                                                                                   8.90                                                           K021423                  Cancer or advanced adenoma/1,330\                         50 ng/mL\                                                            59.6/70.2/18.0\
                                             Alfa Scientific Designs, Inc. (11/9/2005)                                                                                                                                                                                                                                            Cancer or advanced adenoma /86                            Brenner 2010^[@bibr26-2150131917705206]^\                            17.0/89.0/10.0
                                                                                                                                                                                                                                                                                                                                                                                            50 ng/mL\                                                            
                                                                                                                                                                                                                                                                                                                                                                                            Levy 2014^[@bibr33-2150131917705206]^                                

  3                      3                   Hemosure One-Step Immunological Fecal Occult Blood Test^[b](#table-fn8-2150131917705206){ref-type="table-fn"}^ WHPM, Inc. (9/8/2004)                                                         30.28                                                          K041202                  Cancer\                                                   100 ng/mL\                                                           54.5/90.5/2.3\
                                                                                                                                                                                                                                                                                                                                  Advanced adenoma/ 5,343                                   Wong 2015^[@bibr46-2150131917705206]^                                33.1/91.5/17.2

  4                      4                   OC-Light iFOB Test^[b](#table-fn8-2150131917705206){ref-type="table-fn"}^ (8/18/2004 and 3/24/2011) (changing to OC-Light S FIT K143325) (8/24/2015) Polymedco, Inc.                         12.04                                                          K041297                  Cancer\                                                   50 ng/mL\                                                            78.6/92.8/1.65\
                                                                                                                                                                                                                                                                                                                                  Advanced adenoma/ 18,296\                                 Chiu 2013^[@bibr27-2150131917705206]^\                               28.0/93.5/13.3\
                                                                                                                                                                                                                                                                                                                                  Cancer or advanced adenoma/346                            50 ng/mL\                                                            4.0/97.0/11.1
                                                                                                                                                                                                                                                                                                                                                                                            Levy 2014^[@bibr33-2150131917705206]^                                

  5                      5                   Care Fecal Occult Blood Test\                                                                                                                                                                0.00                                                           K051806                                                                                                                                                 None
                                             Epitope Diagnostics, Inc. (10/7/2005)                                                                                                                                                                                                                                                                                                                                                                               

  6                      6                   Care Diagnostic Clarity iFOB Test^[b](#table-fn8-2150131917705206){ref-type="table-fn"}^\                                                                                                    0.61                                                           K052598                                                                                                                                                 None
                                             Care Diagnostic, Inc. (1/26/2010)                                                                                                                                                                                                                                                                                                                                                                                   

  7                      7                   Consult Diagnostics Immunochemical fecal occult blood test^[b](#table-fn8-2150131917705206){ref-type="table-fn"}^\                                                                           1.32                                                           K060463                                                                                                                                                 None
                                             Immunostics, Inc. (7/8/2010)                                                                                                                                                                                                                                                                                                                                                                                        

  8                                          Henry Schein OneStep+ iFOBT^[b](#table-fn8-2150131917705206){ref-type="table-fn"}^\                                                                                                          0.43                                                           K060463                                                                                                                                                 None
                                             Immunostics, Inc. (3/5/2009)                                                                                                                                                                                                                                                                                                                                                                                        

  9                                          Immunostics Inc. hema-screen SPECIFIC Immunochemical Fecal Occult Blood Test^[b](#table-fn8-2150131917705206){ref-type="table-fn"},[b](#table-fn9-2150131917705206){ref-type="table-fn"}^\   4.45                                                           K060463                                                                                                                                                 None
                                             Immunostics, Inc. (6/15/2006)                                                                                                                                                                                                                                                                                                                                                                                       

  10                     8                   CLIAwaived Inc. Rapid Fecal Occult Blood Test\                                                                                                                                               0.00                                                           K061065                                                                                                                                                 None
                                             TECO Diagnostics (11/9/2009)                                                                                                                                                                                                                                                                                                                                                                                        

  11                     9                   Germaine Laboratories Compliance Gold iFOB\                                                                                                                                                  0.00                                                           K063693                                                                                                                                                 None
                                             Tianjin New Bay Bioresearch Co., Ltd. (9/9/2009)                                                                                                                                                                                                                                                                                                                                                                    

  12                                         Forsure One Step Fecal Occult Blood (FOB) Screen Care Test\                                                                                                                                  0.00                                                           K063693                                                                                                                                                 None
                                             Tianjin New Bay Bioresearch Co., Ltd. (5/16/2007)                                                                                                                                                                                                                                                                                                                                                                   

  13                                         Jant Pharmacal Accutest Immunological Fecal Occult Blood Test^[b](#table-fn8-2150131917705206){ref-type="table-fn"}^\                                                                        0.15^[d](#table-fn10-2150131917705206){ref-type="table-fn"}^   K063693                                                                                                                                                 None
                                             Tianjin New Bay Bioresearch Co., Ltd. (12/4/2008)                                                                                                                                                                                                                                                                                                                                                                   

  14                     10                  Jant Pharmacal Accutest Dual Sample Immunological Fecal Occult Blood Test^[b](#table-fn8-2150131917705206){ref-type="table-fn"}^\                                                                                                                           K073431                                                                                                                                                 None
                                             Tianjin New Bay Bioresearch Co., Ltd. (12/4/2008)                                                                                                                                                                                                                                                                                                                                                                   

  15                     11                  BTNX, Inc. Rapid Response Fecal Occult Blood Test^[b](#table-fn8-2150131917705206){ref-type="table-fn"}^\                                                                                    0.49                                                           K070660                                                                                                                                                 None
                                             Alfa Scientific Designs, Inc. (10/5/2007)                                                                                                                                                                                                                                                                                                                                                                           

  16                     12                  Medline iFOB Test\                                                                                                                                                                           0.00                                                           K100817                                                                                                                                                 None
                                             Princeton BioMeditech Corporation (6/26/2015)                                                                                                                                                                                                                                                                                                                                                                       

  17                                         Status iFOBT\                                                                                                                                                                                0.00                                                           K100817                                                                                                                                                 None
                                             Princeton BioMeditech Corporation (10/19/2011)                                                                                                                                                                                                                                                                                                                                                                      

  18                                         Princeton BioMeditech BioSign Immunochemical Fecal Occult Blood Test\                                                                                                                        0.00                                                           K100817                                                                                                                                                 None
                                             Princeton BioMeditech Corporation (7/8/2010)                                                                                                                                                                                                                                                                                                                                                                        

  19                     13                  Germaine Laboratories Inc. Compliance Gold Fecal Occult Blood Test ER\                                                                                                                       0.00                                                           K102664                                                                                                                                                 None
                                             Germaine Laboratories Inc. (4/20/2016)                                                                                                                                                                                                                                                                                                                                                                              

  20                     14                  Rapid Responses™ FIT\                                                                                                                                                                        0.00                                                           K110309                                                                                                                                                 None
                                             Orient Gene Biotech (4/22/2014)                                                                                                                                                                                                                                                                                                                                                                                     

  21                                         Tanner Scientific iFOB One Step Rapid Test\                                                                                                                                                  0.00                                                           K110309                                                                                                                                                 None
                                             Tanner Scientific (9/14/2015)                                                                                                                                                                                                                                                                                                                                                                                       

  22                                         Clarity Diagnostics One-Step Fecal Occult Blood Test\                                                                                                                                        0.00                                                           K110309                                                                                                                                                 None
                                             Clarity Diagnostics (10/6/2015)                                                                                                                                                                                                                                                                                                                                                                                     

  23                     15                  OSOMÂ® iFOB Test^[c](#table-fn9-2150131917705206){ref-type="table-fn"}^\                                                                                                                     0.00                                                           K121397                                                                                                                                                 None
                                             Sekisui Diagnostics, LLC (1/3/2013)                                                                                                                                                                                                                                                                                                                                                                                 

  24                     16                  Beckman Coulter Hemoccult ICT^[b](#table-fn8-2150131917705206){ref-type="table-fn"},[c](#table-fn9-2150131917705206){ref-type="table-fn"}^\                                                  27.16                                                          K961062                  Screening relevant neoplasia/1075                         200 ng/mL^[e](#table-fn11-2150131917705206){ref-type="table-fn"}^\   23.2/95.8/27.6
                                             SmithKline Diagnostics, Inc. (2/28/1997)                                                                                                                                                                                                                                                                                                       Wong 2012^[@bibr44-2150131917705206]^                                

  Non CLIA-waived FITs                                                                                                                                                                                                                                                                                                                                                                                                                                           

  25                     17                  Polymedco OC Auto Micro 80 analyzer^[b](#table-fn8-2150131917705206){ref-type="table-fn"}^\                                                                                                  12.29                                                          K041408                  Cancer\                                                   ≥100 ng/mL\                                                          65.0/94.6/12.7\
                                             Polymedco, Inc. (5/23/2005 and 12/5/2013)                                                                                                                                                                                                                                            Advanced adenoma/1682                                     Rozen 2010^[@bibr39-2150131917705206]^                               26.4/96.4/33.3

  26                     18                  Polymedco OC-Sensor DIANA iFOB Test^[b](#table-fn8-2150131917705206){ref-type="table-fn"}^\                                                                                                  1.34                                                           K092330                  Cancer or advanced neoplasia/1020                         ≥50 ng/mL\                                                           59.6/90.6/26.3
                                             Polymedco, Inc. (1/20/2010 and 12/5/2013)                                                                                                                                                                                                                                                                                                      Huang 2016^[@bibr22-2150131917705206]^                               

                                                                                                                                                                                                                                                                                                                                  Cancer\                                                   100 ng/mL\                                                           73.3/95.5/10.0\
                                                                                                                                                                                                                                                                                                                                  Cancer or advanced neoplasms/2235                         Brenner 2013^[@bibr25-2150131917705206]^                             25.7/97.4/51.8

                                                                                                                                                                                                                                                                                                                                  Cancer\                                                   75 ng/mL\                                                            82.9/60.0/NA\
                                                                                                                                                                                                                                                                                                                                  Advanced adenoma/ 457                                     Crouse 2015^[@bibr28-2150131917705206]^                              49.5/62.7/NA

                                                                                                                                                                                                                                                                                                                                  Cancer\                                                   ≥100 ng/mL\                                                          75.0/95.0/8.0\
                                                                                                                                                                                                                                                                                                                                  Advanced adenoma/1256                                     de Wijkerslooth 2012^[@bibr29-2150131917705206]^                     29.0/97.0/46.0

                                                                                                                                                                                                                                                                                                                                  Cancer\                                                   ≥100 ng/mL\                                                          92.3/90.1/13.8\
                                                                                                                                                                                                                                                                                                                                  Advanced adenoma/770                                      Park 2010^[@bibr38-2150131917705206]^                                33.9/90.6/23.0

                                                                                                                                                                                                                                                                                                                                  Cancer\                                                   ≥100 ng/m\                                                           25.0/NA/NA\
                                                                                                                                                                                                                                                                                                                                  High risk adenomas/3794                                   Sohn 2005^[@bibr43-2150131917705206]^                                6.0/NA/NA

                                                                                                                                                                                                                                                                                                                                  Cancer\                                                   ≥100 ng/mL\                                                          73.8/94.9/6.9\
                                                                                                                                                                                                                                                                                                                                  Advanced precancerous lesions/9989                        Imperiale 2014^[@bibr47-2150131917705206]^                           23.8/94.9/25.7
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: FDA, Food and Drug Administration; CLIA, Clinical Laboratory Improvement Amendments; FIT, fecal immunochemical test; PT, proficiency testing; PPV, positive predictive value; NA, not available.

Shading indicates the same test marketed under different names.

Assessed by Proficiency Testing Programs.

Dry slide collection method.

Proficiency Testing Programs provide only the single sample result.

Taken from manufacturers' product brochure.

Proficiency Testing Programs' Accuracy of FITs {#section13-2150131917705206}
----------------------------------------------

There were 57 433 synthetic stool samples used for analysis of gFOBTs and FITs for the 7 PT programs in 2014. However, no information is available on the types of FOBTs analyzed for the 2552 AAFP-PT samples, leaving 54 881 samples available from 6 PT programs for analysis. Of these, 12 730 (23%) were FITs and 42 151 (77%) were gFOBTs. Of the 12,730 FIT samples, the following FITs were most frequently evaluated: (1) Hemosure One-Step Immunological Fecal Occult Blood Test (30%), (2) Beckman Coulter Hemoccult ICT (27%), (3) OC-Light iFOB (12%), (4) OC-Auto Micro 80 (12%), and (5) QuickVue IFOB (9%). These 5 tests accounted for 90.7% of the FITs evaluated. PT programs evaluated 13 FITs, 11 (9 distinct 510(k) numbers) of the 24 CLIA-waived FITs and 2 automated FITs (see [Table 3](#table3-2150131917705206){ref-type="table"}).

###### 

Proficiency Testing Programs' Fecal Immunochemical Test (FIT) Totals and Accuracy for Spiked Samples by Test System/Manufacturer for 2014.

![](10.1177_2150131917705206-table3)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Test System/Manufacturer/Sample Size/510(k) Number   Total Correct (Percentage Correct)                                                 Total Incorrect (Percentage Incorrect)   Overall Sensitivity, % (95% CI)   Overall Specificity, % (95% CI)                                 
  ---------------------------------------------------- ---------------------------------------------------------------------------------- ---------------------------------------- --------------------------------- --------------------------------- ---------- ------------------ ------------------
  1                                                    Hemosure One-Step Immunological Fecal Occult Blood Test (n = 3854) (K041202)       2189 (99.5)                              1638 (98.9)                       10 (0.5)                          17 (1.1)   99.2 (98.8-99.5)   99.4 (98.9-99.7)

  2                                                    Beckman Coulter Hemoccult ICT\                                                     1819 (98.7)                              1597 (98.9)                       24 (1.3)                          18 (1.1)   99.0 (98.5-99.4)   98.5 (97.8-99.0)
                                                       (n = 3458) (K961062)                                                                                                                                                                                                          

  3                                                    OC-Light iFOB Test\                                                                875\                                     636 (97.5)                        6 (0.7)                           16 (2.5)   98.2 (97.1-98.9)   99.1 (97.9-99.6)
                                                       (n = 1533) (K041297)                                                               (99.3)                                                                                                                                     

  4                                                    QuickVue IFOB Test\                                                                661 (99.5)                               472 (99.6)                        3 (0.5)                           2 (0.4)    99.7 (98.8-100)    99.4 (98.1-99.9)
                                                       (n = 1138) (K021423)                                                                                                                                                                                                          

  5                                                    Immunostics Inc. hema-screen SPECIFIC Immunochemical Fecal Occult Blood Test\      310 (100)                                255 (99.6)                        0                                 1 (0.4)    99.7 (98.0-100)    100 (98.2-100)
                                                       (n = 566) (K060463)                                                                                                                                                                                                           

  6                                                    Consult Diagnostics Immunochemical fecal occult blood test (n = 169) (K060463)     113 (99.1)                               55 (100)                          1 (0.9)                           0          100 (96.1-100)     98.2 (89.7-100)

  7                                                    Henry Schein OneStep+ iFOBT\                                                       36 (100)                                 19 (100)                          0                                 0          100 (88.5-100)     100 (80.2-100)
                                                       (n = 55) (K060463)                                                                                                                                                                                                            

  8                                                    Care Diagnostic Clarity iFOB Test\                                                 49 (100)                                 28 (100)                          0                                 0          100 (91.3-100)     100 (85.7-100)
                                                       (n = 77) (K052598)                                                                                                                                                                                                            

  9                                                    Enterix Insure Fecal Immunochemical Test\                                          40 (100)                                 20 (87.0)                         0                                 3 (13.0)   93.0 (80.7-98.3)   100 (81.0-100)
                                                       (n = 63) (K002457)                                                                                                                                                                                                            

  10                                                   BTNX, Inc. Rapid Response Fecal Occult Blood Test (n = 62) (K070660)               33 (97.1)                                28 (100)                          1 (2.9)                           0          100 (87.6-100)     96.6 (81.4-100)

  11                                                   Jant Pharmacal Accutest Immunological Fecal Occult Blood Test (n = 19) (K073431)   13 (100)                                 6 (100)                           0                                 0          100 (73.4-100)     100 (55.7-100)

  12                                                   OC-Auto Micro 80^[a](#table-fn13-2150131917705206){ref-type="table-fn"}^\          808 (100)                                750 (99.1)                        0                                 7 (0.9)    99.1 (98.2-99.6)   100 (99.4-100)
                                                       (n = 1565) (K041408)                                                                                                                                                                                                          

  13                                                   OC-Sensor Diana^[a](#table-fn13-2150131917705206){ref-type="table-fn"}^\           88 (100)                                 83 (100)                          0                                 0          100 (95.0-100)     100 (94.7-100)
                                                       (n = 171) (K092330)                                                                                                                                                                                                           

                                                       Total (n = 12 730)                                                                 7034                                     5587                              45                                64         99.1 (98.9-99.3)   99.2 (98.9-99.4)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

(shaded area indicate FITs with same 510(k) number).

Automated FITs.

(shaded area indicate FITs with same 510(k) number).

For the waived FITs, sensitivity ranged from 93.0% for Enterix Insure Fecal Immunochemical Test to 100% for 5 test system/manufacturers and specificity ranged from 96.6% for BTNX, Inc Rapid Response Fecal Occult Blood Test to 100% for 5 test system/manufacturers (see [Table 3](#table3-2150131917705206){ref-type="table"}). The automated FIT, OC-Sensor Diana, had a sensitivity of 100% and specificity of 100%, with similar results for the OC-Auto Micro 80.

Literature Review {#section14-2150131917705206}
-----------------

As described in the Methods section, 13 studies presented the accuracy of FITs for AAP and/or CRC, using colonoscopy as the gold standard. Information on FIT accuracy in human studies is available for only 4 CLIA-waived FITs on the US market (see [Table 2](#table2-2150131917705206){ref-type="table"}).^[@bibr26-2150131917705206],[@bibr27-2150131917705206],[@bibr33-2150131917705206],[@bibr44-2150131917705206],[@bibr46-2150131917705206]^ These studies were heterogeneous, conducted on screening or mixed screening, and high-risk populations in Canada,^[@bibr44-2150131917705206]^ China,^[@bibr46-2150131917705206]^ Germany,^[@bibr26-2150131917705206]^ Taiwan,^[@bibr27-2150131917705206]^ and the United States.^[@bibr33-2150131917705206]^ The outcomes differed across studies and were typically either AAP or CRC, or the 2 combined. [Table 2](#table2-2150131917705206){ref-type="table"} shows which products were tested, the size of the study population, the test detection limits, and the sensitivities, specificities, and positive predictive value for the outcome. In general, the sensitivity for any specific outcome varied within product across studies and by outcome across products. The sensitivity for CRC or AAP reported by Levy, et al^[@bibr33-2150131917705206]^ was 4.0% for the Polymedco OC-Light, whereas the much larger study by Chiu et al^[@bibr27-2150131917705206]^ reported 28% sensitivity for AAP and 78.6% for CRC.^[@bibr27-2150131917705206]^ The Levy, et al study had the FIT mailed in for testing, and the Chiu et al study had the specimen collected the day before the colonoscopy, stored in the refrigerator, and brought into the clinic the day of the colonoscopy which may have affected the results. The sensitivity reported for advanced neoplasms or screening relevant neoplasia for the QuickVue IFOB was 59.6%,^[@bibr26-2150131917705206]^ for OC-Light FOB was 28%,^[@bibr27-2150131917705206]^ and for Beckmann Coulter ICT was 23.2%.^[@bibr44-2150131917705206]^ Corresponding specificities were 70.2%, 93.5%, and 95.8%. There were 2 studies that reported sensitivities separately for AAP and colorectal cancer.^[@bibr27-2150131917705206],[@bibr46-2150131917705206]^ The Wong et al study using Hemosure One-Step showed sensitivity for CRC of 54.5% and AAP of 33.1%.^[@bibr46-2150131917705206]^

For the 2 automated FITs, there were 8 studies assessing FIT accuracy (see [Table 2](#table2-2150131917705206){ref-type="table"}).^[@bibr22-2150131917705206],[@bibr25-2150131917705206],[@bibr28-2150131917705206],[@bibr29-2150131917705206],[@bibr38-2150131917705206],[@bibr39-2150131917705206],[@bibr43-2150131917705206],[@bibr47-2150131917705206]^ Sensitivity for AAP across studies was highly variable, from 25.7%^[@bibr25-2150131917705206]^ to 49.5.^[@bibr28-2150131917705206]^ Sensitivity for colorectal cancer varied from 65%^[@bibr39-2150131917705206]^ to 92.3.^[@bibr38-2150131917705206]^ For studies reporting the sensitivity for CRC separately from AAP, sensitivities for colorectal cancer were higher than for AAP.

Discussion {#section15-2150131917705206}
==========

Based on our review of the FDA database, there are 26 unique FITs currently on the U.S. market, with 24 waived under CLIA and two automated tests. FITs comprise 23% of the market based on proficiency testing results, with the rest being gFOBT. The 2 automated tests are used quantitatively in many countries in order to adjust the numbers of individuals sent for diagnostic colonoscopy. These are not approved by the FDA for quantitative analysis in the United States.

Of the 26 FITs on the market, 13 with 11 distinct 510(k) numbers were tested in PT programs. Most FITs tested extremely well with sensitivities for 11 of 13 FITs at 99% or higher and specificities for 10 of the 13 FITs at 99.4% or higher. However, samples used by PT programs are simulated fecal material spiked with an unknown amount of hemoglobin that is likely not at the lower limits of sensitivity for FIT products being assessed. PT programs will not share how much hemoglobin is in their spiked samples, as that is considered proprietary information. Tests used for CRC screening need to be simple, reliable, and test well under usual conditions.^[@bibr50-2150131917705206]^ Health care providers and patients deserve to know that the FITs being used provide accurate test results. There is very little published, population-based research on CLIA-waived FITs done at a single point in time, using colonoscopy as the gold standard. Only 5 studies of 4 unique CLIA-waived FITs (out of 16 total) have been conducted.^[@bibr26-2150131917705206],[@bibr27-2150131917705206],[@bibr33-2150131917705206],[@bibr44-2150131917705206],[@bibr46-2150131917705206]^ The 2 automated FITs have been studied in larger populations than the CLIA-waived FITs and generally have favorable sensitivities and specificities for CRC and/or AAP.^[@bibr22-2150131917705206],[@bibr25-2150131917705206],[@bibr28-2150131917705206],[@bibr29-2150131917705206],[@bibr38-2150131917705206],[@bibr39-2150131917705206],[@bibr43-2150131917705206],[@bibr47-2150131917705206]^

Lee et al^[@bibr51-2150131917705206]^ conducted a systematic review and meta-analysis to assess the diagnostic accuracy of FITs for CRC.^[@bibr51-2150131917705206]^ Nineteen research studies, 2 from the United States, were included in the study with both qualitative and quantitative FITs. The overall sensitivity for CRC across these 19 studies of 113 360 total patients was 79% and specificity was 94%. Sensitivity and specificity was not studied for AAP.^[@bibr51-2150131917705206]^ Another review of 21 studies using either CLIA-waived or automated FITs demonstrated that FITs have a sensitivity for CRC ranging from 0.25 to 1.00 and specificity of 0.83 to 0.99.^[@bibr52-2150131917705206]^ A systematic review and meta-analysis of qualitative FDA-cleared FITs used in US studies would be worthwhile to continue to explore accuracy for CRC and AAP. This cannot be done without more data. Researchers in Germany have evaluated 20 qualitative and 1 quantitative FIT for hemoglobin in spiked samples and determined the detection limits for hemoglobin do not match the manufacturer's specifications.^[@bibr53-2150131917705206]^ German researches recommend screening programs avoid using qualitative FITs due to differences in detection limits with large variations in sensitivity and specificity.^[@bibr54-2150131917705206]^

A good FIT is one that has a high sensitivity and specificity for screening relevant neoplasia. FITs are recommended regularly over time, in order to have the best chance of detecting occult blood. However, in a real-world setting, many issues can affect the sensitivity and specificity of FITs.^[@bibr33-2150131917705206],[@bibr50-2150131917705206],[@bibr55-2150131917705206]^ There is a seasonal variation in FIT results with lower positivity rates in warmer weather, due to degradation of hemoglobin.^[@bibr55-2150131917705206],[@bibr56-2150131917705206]^ Allison et al^[@bibr57-2150131917705206]^ have also recommended all companies use a standard collection device and probe with a known buffer for comparison across studies. There is no accepted international quality control standard for use with FITs.

The AAFP-PT results were excluded because they provided only aggregated data for all FOBTs, thus, it was not known which FITs were evaluated by that program. However, the AAFP-PT was only 4% of the total proficiency tests evaluated. Proficiency testing results do not provide any information on the accuracy of human samples for AAP or CRC. In addition, laboratories performing point-of-care tests are not required to participate in PT programs. This means that there is little to no information on test accuracy for the majority of CLIA-waived tests being used in primary care offices and Federally Qualified Health Centers in the United States.

Based on the 2014 PT program results, the gFOBT accounts for 77% of the FOBTs, even though the FIT has been determined to be a better test for occult blood in the stool. Proficiency test results are a crude measure for determining the percentage of gFOBTs and FITs used in the United States. Among the FITs, Hemosure One-Step Immunological Fecal Occult Blood Test was evaluated the most with the Beckman Coulter product close behind. The current worldwide use of FITs is primarily automated FITs read with quantitative results.^[@bibr22-2150131917705206],[@bibr25-2150131917705206],[@bibr29-2150131917705206],[@bibr39-2150131917705206],[@bibr51-2150131917705206]^ In the United States, 122 671 physician office laboratories use the CLIA-waived FOBTs^[@bibr58-2150131917705206]^ and the quantitative FITs used in other countries are either not available or are only able to report qualitative results because they have not been approved by the FDA to report quantitatively.

The 13 FIT brands tested across the 6 PT programs tested extremely well using spiked samples and might be appropriate to use in CRC screening programs. However, there was published information on only 4 of 24 (16 unique 510(k) numbers) CLIA-waived tests in screening populations and/or populations at higher risk. Given the goal of 80% of individuals screened for colorectal cancer by 2018, it is likely that FITs will need to play a greater role in screening, and an estimated 24 million more Americans will need to be screened.^[@bibr59-2150131917705206]^ Most developed countries have a systematic CRC screening program that uses mailed automated FITs developed in a central or few locations.^[@bibr60-2150131917705206],[@bibr61-2150131917705206]^ A comparative effectiveness study of the test characteristics of commonly used FITs with colonoscopy as the gold standard is essential if we are to know which FITs available in the United States have the best test characteristics. Studies conducted on 4 qualitative, CLIA-waived FITs demonstrate widely varying test accuracy.^[@bibr33-2150131917705206]^ Do the commonly used FIT brands test positive down to the lower limits of hemoglobin specified in their product inserts and under conditions where stool is present? It is critical to determine the FITs with the best test characteristics in order to implement successful FIT-based screening programs.^[@bibr28-2150131917705206],[@bibr32-2150131917705206],[@bibr62-2150131917705206]^

To answer the question, "which FIT do I use?" a FIT is recommended in the CRC screening guidelines in preference to gFOBT.^[@bibr12-2150131917705206],[@bibr13-2150131917705206],[@bibr15-2150131917705206]^ Reviewing the PT program results, 13 FITs evaluated across programs would be appropriate based on spiked samples. However, narrowing the FITs further, based on the studies that conducted a one-time FIT prior to colonoscopy to assess test accuracy for AAP or CRC, the automated FITs (OC-Auto Micro 80 and OC-Sensor Diana), provided the best sensitivities and specificities across studies. Further studies are warranted prior to recommending FITs that are waived under CLIA for private practice offices.
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